ROCKET AF’s Design Causes Headaches For Xarelto Sponsors
Executive Summary
Key design elements of the Xarelto pivotal trial in atrial fibrillation have come back to haunt sponsors Bayer and Johnson & Johnson during the course of the rivaroxaban NDA review.